Academic Qualification
| Qualification | Institution | Year of Completion |
|---|---|---|
| Graduate Certificate in Intellectual Property Law | National University of Singapore | 2016 |
| Dr. rer. nat. (Biochemistry) | Julius-Maximilians University Würzburg | 2013 |
| Dipl.-Biol. (BSc/MSc equivalent) | Julius-Maximilians University Würzburg | 2010 |
Industry Experience
| Position | Organisation/Institution | Date of Tenure |
|---|---|---|
| Research Scientist | Genelux Corporation, San Diego, USA | 2010 - 2013 |
Selected Patent Cooperation Treaty (PCT) Specifications
| PCT Publication Number | Title of Application |
|---|---|
| WO 2016/108758 | Technique for formation and assembly of 3d cellular structures |
| WO 2016/130085 | Dermatopontin as a therapeutic for metabolic disorders |
| WO 2017/146653 | A simple one-step real-time molecular sensor for microrna detection |
| WO 2016/175708 | Microchip-based elisa for rapid serodiagnosis of tuberculosis |
| WO 2017/048197 | Use of niclosamide in the treatment of p53-deficient cells |
| WO 2017/078631 | Chemical-inducible genome engineering technology |
| WO 2017/123161 | Inhibition of intracellular growth of mycobacterium species and its applications (full spec; pct conversion; no claims) |
| WO 2017/160234 | Generation of midbrain-specific organoids from human pluripotent stem cells |
| WO 2017/192102 | Mitochondrial delivery of recombinant nucleic acids |
| WO 2017/217935 | Consequences of a defective switch in cutaneous squamous cell carcinoma (scc) |
| WO 2017/209697 | Genetic alteration in antisense long non-coding rna as a biomarker for susceptibility to disease treatment |
| WO 2018/034620 | Immunosuppressive composition for use in treating immunological disorders |
| WO 2018/056907 | Novel target and methodology to inhibit skin inflammation and blunt skin cancer susceptibility |
| WO 2018/199849 | Characteristic urine metabolites in spontaneous miscarriages |
| WO 2019/070204 | Method for treating natural killer/t-cell lymphoma |
| WO 2019/143292 | Method for differentiation of human pluripotent stem cell lines in suspension culture |
| WO 2019/164451 | Cancer therapeutic targeting using mutant P53-specific siRNAs |
Experience and Technical Background
Experienced in the following areas of patent practice:
- Drafting
- Local and Foreign Patent Prosecution
- Patentability Advice
- Extensions of Patent Term (Pharmaceuticals)
- Patent Searches
Primary patent practice areas by technology:
- Virology
- Biochemistry
- Cloning and Gene editing
- Pharmaceutical Biology
- Molecular Biology
- Proteins
- Cell Biology
- Antibodies
Research/industry background:
A. General technical areas:
- Virology
- Protein (over-) expression and purification
- Pharmacokinetics
- Pharmacodynamics
- Cancer mouse models
- in vivo testing
- blood-based analysis
B. Honours research:
- “Experiments on the Expression of a DLD-fusion protein in Mammalian Cells” at the Institute for Clinical Biochemistry, Würzburg.
- Identified methods for enabling and improving gene expression of the DLD fusion protein
- Focus on gene editing, cloning and protein expression
C. PhD research:
- Dissertation on “Comparative Analysis of Vaccinia Virus-Encoded Markers Reflecting Actual Viral Titres in Oncolytic Virotherapy”: Using viruses to treat cancer is a novel approach to an age-old disease. Oncolytic viruses are native or recombinant viruses that have the innate or enhanced capability to infect tumour cells, replicate within the tumour microenvironment and subsequently lyse those cells. Since imaging modalities offer little insight into viral replication deep within the body, and because oncolytic virotherapy is dependent on replication within the target tissue, the need for a monitoring system is evident. Pharmacokinetic analysis of this oncolytic agent was to give insight into the dynamics present in tumours during treatment. This, in turn, would give clinicians the opportunity to monitor the efficacy as early as possible after the onset of treatment, to observe treatment progression and possibly to gauge prognosis, without resorting to invasive procedures, e.g. biopsies.
- Doctorate Scholarship program between the Julius-Maximilians University Würzburg and Genelux Corporation, San Diego.
D. Industry experience:
- Post as a research scientist at Genelux Corporation, San Diego, working with the Vaccinia virus.